STATEMENT OF NEED

Psoriatic arthritis (PsA) is a chronic, immune-mediated disease that develops in up to 30% of patients with psoriasis. Characterized by inflammation of the skin, nails, entheses, and peripheral and axial joints, PsA can result in progressive join damage, functional disability, and impaired quality of life (Kang & Coates, 2025). The advent of biologic and targeted synthetic agents directed at mediators of specific cytokine pathways—including PDE4, JAK, and TYK2—has significantly improved patient outcomes while providing the flexibility and treatment personalization potential of oral therapy (Goupille et al, 2024; Tsiogkas et al, 2025). In order to optimize the efficacy and safety of targeted therapy, multidisciplinary collaboration between members of the dermatology and rheumatology teams is crucial. In this Multidisciplinary Care Conference, Tina Bhutani-Jacques, MD, MAS, FAAD, Chief Executive Officer of Synergy Dermatology and Associate Clinical Professor at UCSF Dermatology, and Christopher Ritchlin, MD, MPH, Professor in the Division of Allergy, Immunology, and Rheumatology at the University of Rochester Medical Center, will explore strategies for enhancing outcomes with oral targeted therapies in psoriatic arthritis. 

TARGET AUDIENCE

Rheumatologists, dermatologists, and rheumatology and dermatology advanced practice providers involved in the care of patients with psoriatic arthritis.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

• Describe the role of inflammatory cytokines in the pathophysiology of PsA
• Assess risk factors, defining features, and screening tools that can enable the timely identification of PsA
• Appraise the mechanism of action, efficacy, and safety of current and emerging oral small molecule therapies for PsA

REGISTRATION

There is no fee to participate in or claim CME/NCPD/AAPA credit for this activity.

PROVIDED BY

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 3/16/27. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development

A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 1.0 contact hour of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour. 

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Tina Bhutani-Jacques, MD, MAS, FAAD, discloses that she has served on an advisory board or panel for AbbVie, Apogee, Arcutis, Aslan, Boehringer Ingelheim, Bristol Myers Squibb, Castle, Dermavant, Galderma, Incyte, Janssen, Leo, Lilly, Oruka, Pfizer, Novartis, Regeneron, Sanofi, Sun, Takeda, Taxa, and UCB; that she has served on a speaker's bureau for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Galderma, Janssen, Leo, Lilly, Mindera, Ortho, Regeneron, Sanofi, and UCB; and that she has received grants/research support from Amgen, Castle, CorEvitas, Novartis, Pfizer, and Regeneron.

Christopher Ritchlin, MD, MPH, discloses that he has served as a consultant for Johnson & Johnson, Lilly, Moonlake, Novartis, and UCB; and that he has received grants/research support from Johnson & Johnson, Novartis, and UCB. 

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must watch the video and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME/NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME/NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by educational funding provided by Amgen.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.